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The anticancer agent topotecan is considered to be S-phase specific. This implies that cancer cells that are not actively replicating
DNA could resist the effects of the drug. The cycle specificity of topotecan action was investigated in MCF-7 cells, using time-lapse
microscopy to link the initial cell cycle position during acute exposures to topotecan with the antiproliferative consequences for
individual cells. The bioactive dose range (0.5–10mM) for 1-h topotecan exposures was defined by rapid drug delivery and
topoisomerase I trapping. Topotecan caused pan-cycle induction and activation of p53. Lineage analysis of the time-lapse sequences
identified cells initially in S-phase and G2, and defined the time to mitosis for cells originating from G2, S-phase and G1. Topotecan
prevented all mitoses from S-phase cells and G1 cells (half-maximal effects at 0.14mM and 0.96mM, respectively). No dose of
topotecan completely prevented mitosis among G2 cells, and at saturating doses of topotecan about half the cells of G2 origin
continued dividing (the half-maximal effects was at 0.31mM). Overall, topotecan differentially targeted G1-, S- and G2-phase cells, but
many G2 cells were resistant to topotecan, presenting a clear route for cell cycle-mediated drug resistance.
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DNA topoisomerase I is a key target for anticancer therapy because
of its crucial role in DNA metabolism and because it is often
upregulated in cancer cells (O’Leary and Muggia, 1998; Bailly,
2000; Garcia-Carbonero and Supko, 2002). Topoisomerase I acts to
relax the supercoils that accumulate in DNA during DNA
replication (Wang, 1985) and transcription and does not show
any strict cell cycle regulation (O’Leary and Muggia, 1998; Bailly,
2000; Garcia-Carbonero and Supko, 2002). During the relaxation
reaction, a covalent intermediate between topoisomerase I and a 30
single-stranded DNA (ssDNA) break is formed and this complex
can become stabilized in the presence of the anticancer
camptothecins (Hsiang and Lui, 1988; Shah and Schartz, 2001) to
form cleavable complexes. Topotecan, a camptothecin derivative,
is regarded as being S-phase selective (Bailly, 2000) because it is
thought that cleavable complexes lead to dsDNA (double-stranded
DNA) breaks during DNA replication (Hsiang and Lui, 1988; Kohn
et al, 2000). Therefore, it is possible that many cells resist the
effects of topotecan by failing to enter S-phase or replicate DNA
during exposure to the drug (Shah and Schartz, 2001), although the
true extent of this escape remains unclear. Understanding which
cells are affected by camptothecin derivatives, and to what extent,
is critical for the identification of potential mechanisms of cell
cycle-mediated chemotherapy resistance (Shah and Schartz, 2001).
The S-phase selectivity of camptothecins (Gong et al, 1993) is
consistent with the substantial reduction in their cytotoxic actions
when cells are pretreated with the DNA polymerase inhibitor
aphidicolin (Tsao et al, 1992; Wu et al, 2002). However, the use of
replication inhibitors can also inhibit DNA polymerase-dependent
DNA repair processes and can disrupt cycle traverse (Moore and
Randall, 1987). In contrast, experiments involving short-term
treatments with camptothecin derivatives where more than 80% of
cells were killed (O’Connor et al, 1990, 1991) suggest that the
effects of camptothecins are not specific to S-phase cells. Indeed,
camptothecin-induced DNA damage may be produced during
transcription outside of S-phase as well as by DNA replication
during S-phase (Mosesso et al, 2000), in keeping with a wider pan-
cycle activity of topoisomerase I. Furthermore, reports of
immediate G1 checkpoint activation following camptothecin
exposure (Houser et al, 2001; Bozko et al, 2002) indicate the
targeting of G1 cells. However, the eventual cell cycle consequences
of topoisomerase I inhibition are difficult to link with the initial
cell cycle position during the drug exposure period.
In this study, we used a high temporal resolution cell-tracking
approach to measure the immediate pharmacodynamic effects of
1h exposures to topotecan upon MCF-7 cells in each specific cell
cycle phase in order to explore the origins of cell cycle-mediated
resistance to the actions of topotecan. The phase-dependent
consequences of topotecan treatment upon mitosis and apoptosis
were measured without the confounding effects of cell synchro-
nization or metabolic inhibition. Short-term exposures to topote-
can were used in order to limit the cohort of cells undergoing DNA
replication during drug exposure and to limit the confounding
effects of pH-dependent topotecan inactivation (Chourpa et al,
1998). We present new evidence that topotecan directly targets
cells in each cell cycle phase to prevent proliferation and rapidly
induces a p53 response. In addition, we show that some G2 cells
resist all acute doses of topotecan and continue to divide,
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sproviding a persistent route for cell cycle-dependent escape from
topotecan. These pharmacodynamic responses to topotecan are
correlated with topoisomerase I targeting by topotecan.
MATERIALS AND METHODS
Cell culture
Asynchronous MCF-7 cells, obtained from ECCC (Porton Down,
UK), were cultured exclusively in Dulbecco’s modified Eagles
medium with 10% FCS at 371C.
Topotecan
Topotecan (Hycamtin
s, SmithKline Beecham/Merck Pharmaceu-
ticals, UK) was prepared in sterile water and the stock was stored
at  801C until required. MCF-7 cells were seeded at 3 10
4 per
well in standard plastic six-well tissue culture dishes for 24h prior
to treatment with topotecan for 1h at 371C, 5% CO2, followed by
two washes with medium. Controls for drug treatment were
handled in an identical manner, but treated with only sterile water.
Cell cycle analysis
Cell cycle distributions were determined by analysis of ethidium
bromide labelled cells as described (Smith et al, 1999) using a
FacScan flow cytometer (Beckton-Dickinson, Cowley, UK). Cell
cycle distributions were deduced as described by Watson et al
(1987).
DNA content vs p53 levels
Flow cytometry semiquantification of intracellular p53 levels vs
DNA content (propidium iodide staining) was performed similarly
to the method described previously (Gong et al, 1993). The
expression of p53 was detected by labelling the cells using the
DO-1 antibody (a pan-tropic anti-p53 antibody specific for
residues 21–25).
Time-lapse microscopy
MCF-7 populations that had been exposed to topotecan and
washed, as described above, were incubated on the stage of the
microscope in a standard plastic six-well culture dish. The
instrument comprised a Zeiss Axiovert 100 microscope (Zeiss,
Welwyn Garden City, UK) fitted with a temperature regulating
incubator system and CO2 supply (Solent Scientific, Portsmouth,
UK). The motorised xy microscope stage was from Prior Scientific
and the phase transmission images ( 10 objective lens) were
captured every 20min over 48h (145 frames per field) using an
Orca I ER charge-coupled device camera (Hammamatsu, Welwyn
Garden City, UK). The camera, stage (xy) and focus (z) were PC
computer controlled via AQM 2000 software (Kinetic Imaging,
Wirral, UK). Tiff-format Images (512 512 pixels) were played
back for analysis as movies using the AQM 2000 software.
Initially, the time-lapse image sequences were manually
analysed by counting the start and end numbers of cells, and by
manually recording the time and nature of proliferative events
during the observation period. Mitoses were deemed to have added
one cell to the total number, ploidy events to have not changed the
cell number and all cell deaths (whether the cells detached or not)
to have decreased the cell number by one. The data was converted
so that cell number changes were expressed as a percentage change
from the starting number of cells (which ranged, for the
proliferation curves from 288 to 349 cells per drug dose). The
percentage changes in cell number were plotted as a function of
time following the end of the topotecan treatment. Multiple fields
ensured that sufficient numbers of cells were monitored to achieve
the required time resolution. The cell cycle was mapped onto
the proliferation curves using the data from bromodeoxyuridine
(BrdU) time-lapse analysis of control cell populations. As detailed
in the Results section, the expected time window for first-cycle
G2 divisions was 0–8h after topotecan exposure, while that of
G1 cells was 16–20h. S-phase was expected at 8–16h. The
proliferation rates for different cell cycle phases after exposure to
topotecan (0.5–10mM) were measured from the slopes of the
proliferation curves for control cells, and dose–response curves
for each cell cycle phase were plotted and curves fitted using the
nonlinear difference of squares approach. The graph software,
GraphPad Prism (GraphPad.com), generated R
2 values for good-
ness of fit.
In order to identify the cells in S-phase during a topotecan
exposure, the cells were pulse-labelled for 15min with 40mM
bromodeoxyuridine (BrdU) at 371C for 15min and washed twice
in medium immediately prior to the 1h drug treatment. The time-
lapse observations were performed and then the cells fixed and
immunocytochemically stained to detect the BrdU label as
described by Bond et al (1996). Brightfield images of the BrdU-
labelled cells (147–197 total cells, about 30% labelled) within the
time-lapse recorded fields were collected. The brightfield images
were used to locate the BrdU-labelled cells in the time-lapse image
sequences. The labelled cells were backward tracked from 48h
back to 0h to identify the behaviour of cells that had been in S-
phase during the topotecan treatment. Lineage analysis of the
BrdU-labelled S-phase cells mapped the timings of first and
subsequent divisions arising from these cells. Subsequently, G1
and G2 cells were identified by the time of their mitoses,
respectively, after or before S-phase mitoses and their lineages
analysed.
Immunoblotting
Whole-cell lysates were prepared and immunoblotted as described
by Webley et al (2000). p53 was detected using the monoclonal
DO-1 clone (Oncogene Research Products, Nottingham, UK).
Serine-15 phospho-p53 was detected using the rabbit polyclonal
9284 (Cell Signaling Technology Inc., Hertfordshire, UK). Topo-
isomerase I extracts for band depletion assays were prepared
differently (Mo et al, 2000). Topoisomerase I was detected using
clone C-21.2 monoclonal antibody (Beckton-Dickinson Pharmin-
gen, Oxford, UK).
Topotecan uptake assays
Topotecan has a UV excitable chromophore, therefore topotecan
uptake into MCF-7 cells was assayed by flow cytometry (MW and
PJS, manuscript in preparation). The assays were performed by
incubating pretrypsinised MCF-7 cells with 10mM topotecan in
fresh medium with 20mM HEPES. At each time point, signals
derived from excitation at multiline UV (351–355nm) were
collected at FL-4 via a 530/30 filter. The UV fluorescence signals
were acquired and analysed using CELLQuest software (Beckton-
Dickinson Immunocytometry Systems, Cowley, UK). Topotecan
uptake was corrected for control sample autofluorescence.
RESULTS
Topoisomerase I trapping by topotecan in MCF-7 cells is
rapid, dose-dependent and readily reversible
In order to measure the pharmacokinetics of the actions of short
exposures to topotecan in MCF-7 cells, the dose relation for the
trapping of topoisomerase I, the intracellular drug concentration
and the reversibility of topoisomerase I trapping were examined.
The pulse exposure regimen was chosen so that the perturbing
effects of the relatively unstable drug and the discreet responses of
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sthe cells could be resolved with the minimum of cycle traverse
during the treatment period. These data defined the bioactive dose
range for topotecan in MCF-7 cells for the time-lapse experi-
ments. Topoisomerase band depletion Western blots
were performed to measure the topotecan dose relationship with
topoisomerase I trapping. MCF-7 nuclei were extracted to
yield only the topoisomerase I that had not been trapped
into cleavable complexes by topotecan, such that trapping
depleted the immunoblot topoisomerase I band. A plot of the
‘band depletion’ of topoisomerase I, following exposure to
topotecan for 10min is shown in Figure 1A. Topoisomerase I
was trapped into cleavable complexes rapidly and in a dose-
dependent manner. Topoisomerase I trapping approached satura-
tion at 5–10mM.
Topoisomerase I trapping increased with time such that 10mM
topotecan had led to the trapping of 54% of the intracellular
topoisomerase I after 1h (Figure 1B). In contrast to the progressive
trapping of topoisomerase I with topotecan exposure, detection of
the intracellular topotecan levels (both active lactone and inactive
hydroxy acid forms) by flow cytometry revealed that the topotecan
(10mM) rapidly entered cells, and the maximal topotecan
concentration was achieved within 10min (Figure 1B). The
intracellular topotecan concentration then diminished to approxi-
mately 65% of the maximum level by the end of the 1h exposure.
This fall was probably a consequence of lactone-ring hydrolysis of
topotecan (Chourpa et al, 1998) leading to a net decline in the
concentration of lactone–topotecan available for cell entry.
Importantly, cells that had been washed twice following the 1h
exposure rapidly decreased their topotecan content and had
returned to untreated control levels by 30–40min, confirming
that, within the limits of detection, no drug persisted following the
treatments (data not shown). When MCF-7 cells were exposed to
topotecan for 1h, the topotecan washed away and the cells
immediately extracted for topoisomerase I, there was a clear
reduction in enzyme trapping following washing, indicating that
cleavable complexes are rapidly removed when the topotecan is
removed from the external medium (Figure 1C). These data are
consistent with the rapid pharmacodynamic action of topotecan in
MCF-7 cells and the rapid reversibility of cleavable complexes
when topotecan is removed (Kohn et al, 2000).
Time-lapse analysis of the effects of topotecan on cell
proliferation
Time-lapse proliferation analyses were used to investigate the
effects of topoisomerase I inhibition by a discreet 1h pulse
exposure to topotecan. Cell population expansion curves consisted
of plots of the number of cells expressed as a percentage of the
number of cells immediately following the topotecan exposure
(Figure 2). The slopes of these graphs indicate the rates of change
in cell numbers over the 48h period of observation. Overall, MCF-
7 cells exposed to topotecan (0.25–2.5mM) experienced an
immediate slowing of their mitotic rates with cessation of
proliferation at about 8h, followed by dose-dependent proliferative
recoveries beginning around 16h after the topotecan exposure
ended. There was little residual proliferation among cells exposed
to 5 or 10mM topotecan. Flow analysis confirmed that proliferative
recoveries occurred, with resumption of ‘normal’ cell cycle
distributions at 24–48h for cells exposed to 1mM topotecan, but
not 10mM topotecan. Each individual event was plotted separately,
such that the spacing of the points also indicated the rate of event
occurrence, with larger spaces (gaps) in the plots at times where
very few proliferative events occurred. In particular, the gaps
between 8 and 16h following topotecan treatment indicated that
cells expected to enter mitosis during this period did not, while the
downward trend in cell numbers over this period indicated that
some cell loss (deaths) occurred.
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Figure 1 Topotecan rapidly enters MCF-7 cells to trap topoisomerase I. (A) Topotecan had trapped topoisomerase I into cleavage complexes, within
10min, depleting the topoisomerase I bands, as detected by immunoblot. Topoisomerase I band depletion was dose dependent as demonstrated in a plot of
topoisomerase I band intensity vs topotecan dose after a 10min incubation period. (B) The intracellular topotecan concentration (J) and topoisomerase I
trapping (K) during a 1h incubation of MCF-7 cells with 10mM topotecan are compared. The maximal intracellular drug concentration was achieved within
10min as measured by flow cytometry (mean fluorescence intensity, channel number). Intracellular topotecan concentrations declined over the following
50min. In contrast, topoisomerase I trapping increased over a 1h incubation with 10mM topotecan. (C) Immunblot topoisomerase I band depletions
following 1h incubations at 0–20mM are shown before (lanes 1–4) and immediately after washing twice (lanes 5–8) with medium to remove the
topotecan. The dose of topotecan to which each of the samples had been exposed is indicated in mM.
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sBrdU labelling of S-phase cells allows the initial cell cycle
position of each cell to be deduced
To identify the cells that were in S-phase during the topotecan
exposure period, MCF-7 cells were pulse labelled with BrdU for
15min immediately before the topotecan exposure and time-lapse
observation. BrdU prelabelling did not alter MCF-7 growth (data
not shown). Backward tracking identified the cells were in S-phase
during the topotecan exposure. There were 58 control cells (out of
197 total) that were in S-phase during the drug treatment period
and 55 of these cells underwent mitosis. The timing of mitoses for
the cohort of untreated MCF-7 cells that were in S-phase (first and
second divisions) during the topotecan exposure period are plotted
as a frequency histogram (inset Figure 2). The S-phase cell mitosis
period was defined as the time-window during which the S-phase
mitosis rate exceeded 50% of its maximum. Therefore, the first
divisions of S-phase cells were defined as occurring 8–16h after the
treatment period ended and the divisions of their daughters
(second divisions) at 28–36h. The expected time window for first-
cycle G2 divisions was 0–8h after topotecan exposure, while that of
G1 cells was after the first-cycle S-phase divisions, but 48h before
the second cycle S-phase divisions, that is, 16–20h. Confirmation
of this timing came from analysis of the distribution of second
divisions from the G2 cells at 22–30h after the drug treatment
period. The duration of S-phase was 8h, a complete cell cycle was
approximately 20–22h, G2E8h and G1E6h.
Single-cell analysis allows the quantification of the
differential effects of topotecan on G1, S and G2 phases
Identification of the time periods when G2, S-phase then G1
cells would be expected to deliver to mitosis, derived from
unperturbed untreated control cell data meant that the mitosis
rates for cells exposed to topotecan (0.5–10mM) could be measured
separately for G2, S-phase and G1 originating cells (Figure 3).
The cells that were in G2 during the drug treatment period
were prevented from reaching mitosis by topotecan in a
dose-dependent manner (Figure 3A), with the expansion rate
following higher doses of topotecan being reduced to approxi-
mately half that of untreated controls. Following exposure to any
topotecan concentration (0.5–10mM), the G2 cells were not
completely prevented from entering mitosis. The relatively
noisy dose-response curve (goodness of fit R
2¼0.55) during
this period reflects the relative paucity of mitoses. Lineage analysis
of G2 cells (from a BrdU-labelled cohort) that had been exposed
to topotecan was limited because the topotecan-treated G2 cells
that failed to divide during 0–8h after the drug treatment period
could not be identified. However, lineage analysis of the 22
escaping G2 cells revealed that following 1mM topotecan exposure
the number of daughter cells undergoing a second-round mitosis
(11) was closely matched by the number dying (10), so that
second-generation events arising from G2 cells caused no net
change in cell number (Figure 2). This contrasts with the MCF-7
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Figure 2 The dose dependency of the effects of 1h topotecan exposures upon MCF-7 cell population expansion curves. The typical effects of 1h
exposures to topotecan upon the numbers of MCF-7 cells in cohorts of 288–349 cells are shown. The cell population sizes are expressed as the percentage
of the size of each culture at time¼0h, the time immediately following the end of the topotecan exposure period. Each proliferative event is plotted as a
single symbol, such that if few events occurred during a time period, gaps appear in the plot. The time-lapse observations were made at 20min intervals.
Control¼(E); 0.5mM¼(W); 1mM¼(B); 2.5mM¼(K); 5mM¼(J); 10mM¼(’). Inset: the timing of mitoses for untreated BrdU-labelled cells. In the
histogram, the timings of first divisions (black filled bars) directly from BrdU-labelled S-phase cells and the second divisions (white bars) from the daughters of
those BrdU-labelled S-phase cells are depicted.
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expected among cells from all observed cells. Importantly,
following exposure to topotecan (0.5–10mM), the surviving
second-generation cells continued to divide providing a route by
which some G2 cell lineages might survive the cytotoxic actions of
topotecan.
When the S-phase cells would be expected to divide, 8–16h after
the drug treatment period, topotecan (0.5–10mM) resulted in a net
loss in cell number (Figure 3B). Interestingly, this S-phase
targeting remained saturated even after exposure to low doses of
topotecan (100nM for 1h, data not shown). BrdU lineage analysis
of the time-lapse data allowed the direct identification of S-phase
cells, such that the complete cessation of mitosis from S-phase cells
following exposure to topotecan (0.5–10mM) could be directly
observed. For example, following exposure to 1mM topotecan all 68
S-phase cells (out of a total of 199 cells) failed to enter mitosis.
Topotecan reduced the rate of mitosis among G1 cells in a dose-
dependent manner. As with S-phase cells, the maximal effect was
that topotecan prevented all divisions from G1 cells (Figure 3C),
but half-maximal responses required a higher concentration of
topotecan (0.96mM) than S-phase cells (0.14mM). Therefore, G1
cells were approximately seven-fold less sensitive to topotecan
than S-phase cells. The targeting of G1 cells by topotecan was
demonstrated by their failure to enter mitosis at 16–20h. It
remains uncertain from the time-lapse data alone whether G1 cells
exposed to 0.5–2.5mM topotecan were delayed or completely
prevented from entering mitosis. However, following exposure to
5–10mM topotecan, very few cells at all entered mitosis during the
48h observation period. The mitosis rates 20–48h after topotecan
exposure (Figure 3D) were reduced in a dose-dependent manner,
reflecting the net effects of the differential cell cycle targeting by
topotecan upon the overall residual proliferative capacity of the
MCF-7 cells.
Topotecan causes the multipoint slowing of cell cycle
traverse, with G2 arrest
Although the single-cell analyses have shown that topotecan
prevented G1- and S-phase cells from reaching mitosis, it remained
unclear whether G1- and S-phase cells continued to traverse the
cell cycle. Previously, cell cycle analysis of the effects of
camptothecin derivatives has shown them to generate transient
S-phase peaks followed by G2 arrest (Tsao et al, 1992). The effects
of topotecan (1 and 10mM for 1h) upon the cell cycle distribution
17h later was measured. This time period was chosen such that
cells in G1 during the drug treatment period should, if
unperturbed, have traversed the cell cycle and reached mitosis.
At 17h, the cell cycle distributions were as follows: control G1
46.2%, S 41.3% and G2 12.5%; 1mM topotecan treated: G1 28.6%, S
32.5%, G2 38.8%; 10mM topotecan: G1 32.8%, S 32.3%, G2 34.8%.
When MCF-7 cells were exposed to topotecan, there was a
substantial accumulation of cells in G2, confirming that cells are
prevented from entering mitosis by topotecan. It was also clear
that there was significant emptying of the G1 fraction, indicating
that G1 cells continue to traverse the cell cycle following exposure
to topotecan. The traversing G1 cells would have passed into S-
phase, so the reduced S-phase fraction 17h after topotecan
treatment demonstrated that S-phase cells, too, continued to
traverse the cell cycle. In the time-lapse sequences, it was observed
that most nondividing cells continued to increase in size, such that
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Figure 3 Dose–response curves for the effects of topotecan upon G2, S-phase and G1 cells, respectively, are shown. Based upon the expected mitosis
rate, the effects of 1-h incubations with topotecan (0–10mM) upon mitosis rates for (A) G2 cells (R
2¼0.56) (B) S-phase cells (R
2¼0.99) and (C) G1 cells
(R
2¼0.93) are shown. The subsequent residual proliferative capacity of the whole-cell populations after all first cycle divisions is shown in (D). Estimates of
maximal decrease in mitosis rate (response, Mmax) and the topotecan dose required to achieve half-maximal response D1/2 were made from curves fitted to
the data points: G2 Mmax¼55.76%, D1/2¼0.31mM; S-phase Mmax¼ 8.1%, D1/2¼0.14mM;G 1Mmax¼ 23.9%, D1/2¼0.96mM.
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scells exposed to 10mM topotecan did not expand in numbers but
did increase in surface area to cover the culture surface during the
48h observation period.
Topotecan exposure leads to rapid stress responses in all
cell cycle phases
The pan-cycle activation of p53 in response to 20mM camptothecin
has been recently described (Houser et al, 2001), indicating that
pan-cycle genotoxic stress is induced by short exposure to
camptothecin, albeit against an apoptotic background. The
activation of the tumor suppressor protein p53 plays an important,
though not essential, role in the activation of the responses of
the genotoxic stress pathways (Schartz and Rotter, 1998). The
activation of p53 may even provide a means to distinguish the
consequences of genotoxic dsDNA break induction from less-toxic
ssDNA break formation (Nelson and Kastan, 1994). The elevation
of p53 protein levels was detected, by flow cytometry, using the
DO-1 antibody, immediately following a 1h exposure to topotecan.
The p53 levels peaked at 3h post-treatment (Figure 4A) and had
diminished rapidly, back almost to control levels by 12h (not
shown). However, we have consistently observed that a 1h
exposure to 2.5mM topotecan caused a greater elevation of p53
levels than exposure to 10mM topotecan (Figure 4A). Cells in S-
phase and G2/M had the highest p53 levels following topotecan
exposure. Among the G0/G1 fraction, p53 was induced in only a
subset of the cells (Figure 4A) giving an elevated mean
fluorescence intensity.
In contrast to the results seen by flow cytometry, Western
blotting of extracts of cells exposed to 10mM topotecan showed that
the levels of p53 peaked at 6h and remained high over the 48h
observation period (Figure 4B). This suggests epitope masking of
the DO-1 antigen (for flow cytometry) following the induction of
p53, indicating that the localization and functions of p53 may have
been changed by exposure to topotecan. Further evidence of that
topotecan caused a stress response was that p53 was phosphory-
lated at serine-15 following exposure to 1 and 10mM topotecan for
1h and remained activated during the 48h observation period
(Figure 4C).
DISCUSSION
In order to investigate cell cycle-mediated resistance to topotecan
(Shah and Schartz, 2001), we have used a single-cell tracking
approach to the analysis of high temporal resolution time-lapse
sequences. For the first time, we have shown that the individual
cell-cycle position of cell at a given period in time maybe linked
with the proliferative outcome for that same cell without
perturbation by metabolic inhibitors or synchronization. The
study reveals the significant differential actions of topotecan across
the cell cycle resulting in rapid induction of stress responses and
failure to engage mitosis. The data presented shows that topotecan
induced cellular stress is immediate in S-phase, G1 and G2 cells
and that, therefore, replicon collision with cleavable complexes
does not represent the sole mechanism of topotecan-induced
stress. Here, we identify cells in G2 that are capable of escaping
topoisomerase I inhibition, with major implications for the design
rationale for the scheduling of topotecan anticancer therapy.
MCF-7 cells were chosen for this investigation given the
widespread use of the cell line in breast cancer research and
because they are relatively resistant to rapid DNA damage-induced
apoptosis, in part because of deficiencies in caspase 3 (Janicke et al,
1998) and p73 (Zhu et al, 2001). Reduced early commitment to
apoptosis eliminated the prejudicial effects of the loss of cells to a
‘dying fraction’. The pharmacokinetic profiles of topotecan with
MCF-7 cells were investigated in order to determine the relation
between topotecan uptake and cleavable complex formation and to
define the bioactive dose range for MCF-7 cells. Topotecan rapidly
entered MCF-7 cells to trap topoisomerase I into cleavable
complexes. Interestingly, topoisomerase I trapping was both
topotecan dose- and time-dependent, while the intracellular
topotecan concentration peaked within 10–12min, and then
declined. Our experiences with other cell lines is that total
topotecan never reaches a steady-state equilibrium (Smith et al,
2002 and manuscript submitted). Lactone–topotecan can cross
cell membranes, while the net charge on hydroxy acid topotecan
prevents cross-membrane diffusion (Gabr et al, 1997). Initially, the
proportion of external lactone–topotecan is high and this drives
the cellular accumulation of topotecan in combination with high-
affinity intranuclear lactone–topotecan binding, resulting in the
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Figure 4 The levels of p53 across the cell cycle are increased rapidly by topotecan exposure. These changes are shown over time, following 1h exposures
to topotecan which ended at t¼0h.(A) Density plots of p53 vs cell cycle at the overall peak p53 levels (at 3h) are shown, following exposure to 0, 2.5 and
10mM topotecan. (B) Western blot to show the levels of p53 protein in MCF-7 cells at 0–24h following exposure to 10mM topotecan for 1h. The
increased p53 levels persisted at 48h (not shown). (C) A Western blot showing that p53 was phosphorylated at serine-15 indicating activation of the
protein following exposure to topotecan for 1h. The time in hours following exposure to 0mM (control), 1 and 10mM topotecan is shown above each band.
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sintracellular topotecan concentration being greater than in the
extracellular medium, peaking after 10–12min. Subsequently, the
total cellular drug concentration falls as lactone–topotecan diffuses
back out of the cell during a continual equilibration between the
high-concentration intracellular lactone–topotecan pool and the
diminishing extracellular topotecan pool subject to lactone ring
hydrolysis (Smith et al, 2002 and manuscript submitted).
In this study, trapping of topoisomerase I was progressive with
time during a 1h incubation with 10mM topotecan, in the face of a
declining intracellular topotecan concentration. Therefore, it is not
the intracellular topotecan concentration (active plus inactive
drug) per se that determines the targeting of the enzyme and the
levels of cleavable complex formation. Indeed, it seems that the
presence of topotecan in a cell leads to progressive topoisomerase I
trapping that is irreversible until the drug is removed from the
surrounding medium and it may be that there is some localization
of topotecan at topoisomerase I sites that determines the levels of
cleavable complex formation. The exact kinetics of cleavable
complex formation and removal are complex because of the
instability of active lactone topotecan and because cleavable
complexes may not be directly reversed, but rather removed by
enzyme action (Yang et al, 1996) and the DNA damage
subsequently repaired.
It was found that topotecan (0.5–10mM) was active against all S-
phase cells and acts in a dose-dependent manner against G1 and
G2 cells. Crucially, it was found that position in the cell cycle
during topotecan exposure alters the sensitivity to topotecan and
the net proliferative outcome. These observations are in keeping
with the previous reports that camptothecins may cause DNA
damage outside of S-phase (O’Connor et al, 1990, 1991; Mosesso
et al, 1999, 2000) and reveal the surprisingly large extent of non-S-
phase targeting by these topoisomerase I inhibitors. Exposure of
MCF-7 cells to topotecan resulted in the rapid elevation of p53
levels in all cell cycle phases. Not all of the G0/G1 (2n) cells showed
p53 induction; however, time-lapse analysis of the control cell
populations indicated that around 30% of an untreated MCF-7 cell
population did not divide over a 48h observation period, it is
probable that many of the nonresponsive 2n cells were in G0.
Overall, the p53 induction data provided an indication that
topotecan caused rapid genotoxic stress to cells in G1-, S- and G2-
phases and this showed that topotecan acted immediately in the
non-S-phase cells confirming that DNA replication was not a
prerequisite for topotecan-induced cellular stress in non-S-phase
cells. Activation of p53 by phosphorylation at serine-15 was also
rapid and persisted for 48h after exposure to 1 or 10mM topotecan
for 1h.
An increasing proportion of G1 cells was arrested with
increasing dose of topotecan, suggesting heterogeneity in the
sensitivity of these cells to topotecan. Surprisingly, the G1 cells
proved only seven-fold less sensitive to topotecan compared to S-
phase cells. The fate of the G2 cells was more complex.
Interestingly, whatever the dose of topotecan (1h), not all of the
G2 cells were prevented from undergoing mitosis. It is important
to note that while many G2 cells were prevented from entry to their
first mitosis by topotecan, others resisted its effects and divided. It
was found that the daughter cells from G2 cells were subject to
abnormally high levels of apoptosis, but importantly some G2
daughters were left to continue to subsequent divisions. Single-cell
analysis therefore showed that G2 cell lineages could survive
topotecan-mediated cytotoxicity because of their cell cycle
position, indicating that, in response to topotecan, caspase 3-
independent apoptosis may be triggered only in cells that have
subsequently passed through mitosis. This is a strong evidence
that cell cycle-mediated resistance to camptothecin derivatives and
perhaps topoisomerase I inhibitors in general can arise from G2
cells.
Analysis of the cell cycle perturbations as a result of exposure to
topotecan complemented the time-lapse data and showed that
topotecan caused cellular stress, leading to G2 checkpoint
activation. To study the cell cycle dependency of the effects of
topotecan, single 1h pulse exposures were used to minimise the
extent of ongoing cycle traverse during the treatment period. It was
found that topotecan slowed G1- and S-phase traverse, with a
significant cohort of cells accumulating in S-phase before a later
marked G2 arrest. Consistent with previous observations, we
confirmed that continuous exposures to topotecan led to slowing
of cell cycle traverse for G1- and S-phase cells, with accumulation
of cells at G2.
These results have implications for the rational scheduling and
combination of topotecan in anticancer therapy. Currently, the
practice is to deliver longer-term lower-dose topotecan in order to
target each tumour cell as it is recruited into S-phase (Herben et al,
1996; Garcia-Carbonero and Supko, 2002). However arrested and
residual slow cycling cells would be expected to avoid such
recruitment (Shah and Schartz, 2001). In this study, we have shown
that non-S-phase cells can be targeted by topotecan, therefore it is
possible that non-S-phase cells, when targeted suboptimally may
be delayed from reaching their optimal window for exposure to
topotecan in a subsequent S-phase. The targeting of such escaping
cells, particularly those of G2 origin may be a useful concept in the
rational development of topotecan schedules, particularly in
combination with other therapies.
REFERENCES
Bailly C (2000) Topoisomerase poisons and suppressors as anticancer
drugs. Curr Med Chem 7: 39–58
Bond J, Haughton M, Blaydes J, Gire V, Wynford-Thomas D, Wyllie F
(1996) Evidence that transcriptional activation by p53 plays a direct role
in the induction of cell senescence. Oncogene 13: 2097–2104
Bozko P, Larsen AK, Raymond E, Skladanowski A (2002) Influence of G2
arrest on the cytotoxicity of DNA topoisomerase inhibitors toward
human carcinoma cells with different p53 status. Acta Biochim Pol 49:
109–119
Chourpa I, Millot JM, Sockalingum GD, Riou JF, Manfrait M (1998) Kinetics
of lactone hydrolysis in antitumor drugs of camptothecin series as studied
by fluorescence spectroscopy. Biochim Biophys Acta 1379: 353–366
Gabr A, Kuin A, Aalders M, El Gawly H, Smets LA (1997) Cellular
pharmacokinetics and cytotoxicity of camptothecin and topotecan at
normal and acidic pH. Cancer Res 57: 4811–4816
Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical
experience, pharmacology and continued development of the camp-
tothecins. Clin Cancer Res 8: 641–661
Gong JP, Li X, Darzynkiewicz Z (1993) Different patterns of apoptosis of
HL-60 cells induced by cyclohexamide and camptothecin. J Cell Physiol
157: 263–270
Herben VMM, ten Bokkel Huinink WW, Beijen JH (1996) Clinical
pharmacokinetics of topotecan. Clin Pharmacokinet 2: 85–102
Houser S, Koshlatyi S, Lu T, Gopen T, Bargonetti J (2001) Camptothecin
and Zeocin can increase p53 levels during all cell cycle stages. Biochem
Biophys Res Commun 289: 998–1009
Hsiang YH, Lui LF (1988) Identification of mammalian DNA topoisomerase
I as an intracellular target of the anticancer drug camptothecin. Cancer
Res 48: 1722–1726
Janicke RU, Sprengat ML, Wal MR, Porto AG (1998) Caspase 3 is required
for DNA fragmentation and morphological changes associated with
apoptosis. J Biol Chem 273: 9357–9360
Kohn KW, Shao R-G, Pommier Y (2000) How do drug-induced
topoisomerase I-DNA lesions signal to the molecular interaction network
that regulates cell cycle checkpoints, DNA replication, and DNA repair.
Cell Biochem Biophys 33: 175–180
Tracking the cell cycle origins of escape from topotecan
GP Feeney et al
1316
British Journal of Cancer (2003) 88(8), 1310–1317 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sMo Y-Y, Wang PC, Beck WT (2000) Functional expression of human DNA
topoisomerase I and its subcellular localization in HeLa cells. Exp Cell
Res 256: 480–490
Moore RC, Randall C (1987) Different effects of 1-beta-D-arabinofurosyl-
cytosine and aphidicolin in S-phase cells – chromosome-aberrations, cell
cycle delay and cytotoxicity. Mutat Res 178: 73–80
Mosesso P, Fonti E, Bassi L, Garcia CL, Palitti F (1999) The involvement of
chromatin condensation in camptothecin-induced chromosome breaks
in G0 human lymphocytes. Mutagenesis 14: 103–105
Mosesso P, Pichierri P, Franchitto A, Palitti F (2000) Evidence that
camptothecin-induced aberrations in the G2 phase of the cell cycle of
Chinese hamster ovary (CHO) cell line is associated with transcription.
Mutat Res 452: 189–195
Nelson WG, Kastan MB (1994) DNA strand breaks: the template alterations
that trigger p53-dependent DNA damage response pathways. Mol Cell
Biol 14: 1815–1823
O’Connor PM, Kerrigan D, Bertrand R, Kohn KW, Pommier Y (1990) 10,11-
methylenedioxycamptothecin, a topoisomerase I inhibitor of increased
potency: DNA damage and correlation to cytotoxicity in human colon
carcinoma (HT-29) cells. Cancer Commun 2: 395–400
O’Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn
KW, Pommier Y (1991) S-phase population analysis does not correlate with
the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in
human colon carcinoma HT-29 cells. Cancer Commun 3: 233–240
O’Leary J, Muggia FM (1998) Camptothecins: a review of their development
and schedules of administration. Eur J Cancer 34: 1500–1508
Schartz D, Rotter V (1998) p53 dependent cell cycle control: response to
genotoxic stress. Semin Cancer Biol 8: 325–336
Shah MA, Schartz GK (2001) Cell cycle-mediated drug resistance: an
emerging concept in cancer therapy. Clin Cancer Res 7: 2168–2181
Smith PJ, Wiltshire M, Chin SF, Rabbitts P, Soues S (1999) Cell cycle
checkpoint evasion and protracted cell cycle arrest in X-irradiated small-
cell lung carcinoma cells. Int J Radiat Biol 75: 1137–1147
Smith PJ, Wiltshire M, Feeney GP, Shelley M, Chappell MJ, Evans ND,
Ameer-Beg S, Vojnovic B, Errington RJ (2002) Mapping and modeling of
anti-cancer drug–DNA interactions in live tumour cells using time-lapse
two-photon imaging and a two-photon ‘dark’ quenching probe.
Cytometry 36: S11
Tsao YP, Darpa P, Lui LF (1992) The involvement of active DNA-synthesis
in camptothecin-induced G2 arrest – altered regulation of p34 CDC2
cyclin-B. Cancer Res 52: 1823–1829
Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665–697
Watson JV, Chambers SH, Smith PJ (1987) A pragmatic approach to
the analysis of DNA histograms with a definable G1 peak. Cytometry 8:
1–8
Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, Wynford-
Thomas D (2000) Posttranslational modifications of p53 in replicative
senescence overlapping but distinct from those induced by DNA damage.
Mol Cell Biol 20: 2803–2808
Wu JX, Yin MB, Hapke G, Toth K, Rustum YM (2002) Induction of biphasic
DNA double strand breaks and activation of multiple repair protein
complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camp-
tothecin. Mol Pharmacol 61: 742–748
Yang SW, Burgin AB, Huizenga BN, Robertson CA, Yao KC, Nash HA
(1996) A eukaryotic enzyme that can disjoin dead-end covalent
complexes between DNA and type I topoisomerases. Proc Natl Acad
Sci USA 97: 4046–4051
Zhu J, Nozell S, Wang J, Jiang J, Zhou W, Chen X (2001) p73 cooperates
with DNA damage agents to induce apoptosis in MCF7 cells in a p53
dependent manner. Oncogene 20: 4050–4057
Tracking the cell cycle origins of escape from topotecan
GP Feeney et al
1317
British Journal of Cancer (2003) 88(8), 1310–1317 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s